These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25437291)

  • 21. The earlier the better: Alzheimer's prevention, early detection, and the quest for pharmacological interventions.
    Leibing A
    Cult Med Psychiatry; 2014 Jun; 38(2):217-36. PubMed ID: 24668497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antirheumatic prophylaxis and state health administration].
    CHIAROTTI C
    Reumatismo; 1962; 14():89-94. PubMed ID: 13878910
    [No Abstract]   [Full Text] [Related]  

  • 23. [Application of anti-rheumatic drugs in prevention of acute forms of rheumatism].
    IASINOVSKII MA; SAVEL'EV Ia; NAUMOV FG; FINGER OA; SHUTYI MS
    Klin Med (Mosk); 1956 Jun; 34(6):31-40. PubMed ID: 13346948
    [No Abstract]   [Full Text] [Related]  

  • 24. [ScreenGPT - The opportunities and limitations of artificial intelligence in primary, secondary and tertiary prevention].
    Angyal V; Bertalan Á; Domján P; Dinya E
    Orv Hetil; 2024 Apr; 165(16):629-635. PubMed ID: 38643476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Scientific bases of medical examinations of patients with rheumatic diseases].
    Ivanova MM
    Vestn Ross Akad Med Nauk; 1998; (12):19-22. PubMed ID: 9987954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translating curcumin to the clinic for lung cancer prevention: evaluation of the preclinical evidence for its utility in primary, secondary, and tertiary prevention strategies.
    Howells LM; Mahale J; Sale S; McVeigh L; Steward WP; Thomas A; Brown K
    J Pharmacol Exp Ther; 2014 Sep; 350(3):483-94. PubMed ID: 24939419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin Use in Very Elderly Individuals, 1999-2012.
    Johansen ME; Green LA
    JAMA Intern Med; 2015 Oct; 175(10):1715-6. PubMed ID: 26301475
    [No Abstract]   [Full Text] [Related]  

  • 28. Discontinuation of statins in a population of older New Zealanders with limited life expectancy.
    Nishtala PS; Gnjidic D; Chyou T; Hilmer SN
    Intern Med J; 2016 Apr; 46(4):493-6. PubMed ID: 27062205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventive health: time for change.
    Kopes-Kerr C
    Am Fam Physician; 2010 Sep; 82(6):610-4. PubMed ID: 20842988
    [No Abstract]   [Full Text] [Related]  

  • 30. [Cardiovascular risk in the 21st century: identifying risk in primary prevention. Controlling risk in secondary prevention].
    Mazón-Ramos P
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65 Suppl 2():3-9. PubMed ID: 22921168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rheumatic fever in New Zealand.
    Webb R; Wilson N
    J Paediatr Child Health; 2013 Mar; 49(3):179-84. PubMed ID: 22050578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data.
    Eriksson JK; Askling J; Arkema EV
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-147-9. PubMed ID: 25365105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccination recommendations of the Commission for Pharmacotherapy of the German Society of Rheumatology].
    Warnatz K; Goldacker S; Gause AM;
    Z Rheumatol; 2013 Sep; 72(7):687-9. PubMed ID: 23929238
    [No Abstract]   [Full Text] [Related]  

  • 35. Interventions for cardiovascular disease prevention.
    Gupta R; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):15-34. PubMed ID: 21257098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.
    da Silva MA; Martins A; Teixeira AA; Reis RL; Neves NM
    Tissue Eng Part B Rev; 2010 Jun; 16(3):331-9. PubMed ID: 20025434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Living Lab MACVIA. Chronic diseases].
    Avignon A; Fesler P; Daien C; Costa D; Picot MC; Roubille F; Sultan A; Viarouge-Reunier C; Attalin V; Badin M; Boegner C; Demoly P; Dauzat M; David M; Lognos B; Morel J; Pasquié JL; Ribstein J; Granier S; Combe B; Mercier J; Bourret R; Bousquet J
    Presse Med; 2015 Nov; 44 Suppl 1():S47-54. PubMed ID: 26476755
    [No Abstract]   [Full Text] [Related]  

  • 38. Preclinical inflammatory rheumatic diseases: an overview and relevant nomenclature.
    Raza K; Gerlag DM
    Rheum Dis Clin North Am; 2014 Nov; 40(4):569-80. PubMed ID: 25437278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary prevention of rheumatic disease.
    Wigley R
    J Rheumatol; 1993 Apr; 20(4):605-6. PubMed ID: 8496850
    [No Abstract]   [Full Text] [Related]  

  • 40. The heart of the matter: reducing CVD risk.
    Hayman LL; Kamau MW; Stuart-Shor EM
    Nurse Pract; 2009 May; 34(5):30-5. PubMed ID: 19390396
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.